Analyst picks & changes

Cor Therapeutics Inc.


Cowen & Co.'s Lonergan reiterated a "strong buy" on CORR, recommending that investors buy aggressively below $15, following the announcement of the South San Francisco company's strategic partnership with

Schering-Plough Corp.


Read the full 371 word article

How to gain access

Continue reading with a
two-week free trial.